Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | RAD51B del |
Therapy | Olaparib + Temozolomide |
Indication/Tumor Type | uterus leiomyosarcoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RAD51B del | uterus leiomyosarcoma | predicted - sensitive | Olaparib + Temozolomide | Case Reports/Case Series | Actionable | In a clinical case study, Lynparza (olaparib) and Temodar (temozolomide) combination treatment resulted in stable disease and progression-free survival lasting 980 days in a patient with advanced uterine leiomyosarcoma harboring a homozygous deletion of RAD51B (PMID: 37467452). | 37467452 |
PubMed Id | Reference Title | Details |
---|---|---|
(37467452) | Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250). | Full reference... |